25 results on '"J.-M. Pawlotsky"'
Search Results
2. Vorhersage des virologischen Ansprechens bei HCV Genotyp 1a-infizierten Patienten anhand eines Aminosäure Musters im NS5A Protein
3. 1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL
4. 1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV
5. 620 Presence of CD4-positive cells in the portal tract on pretreatment liver biopsy is associated with early viral reduction during antiviral treatment of HCV
6. 771 SEQUENCE ANALYSIS OF THE HBV PreC/C REGION BY ULTRA-DEEP PYROSEQUENCING AS A PREDICTOR OF ADEFOVIR TREATMENT OUTCOME IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
7. 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
8. 483 Metabolic, but not virus-induced steatosis, is related with liver disease severity in chronic hepatitis C
9. 1095 25-OH-VITAMIN D LEVEL IS NOT ASSOCIATED WITH THE OUTCOME OF ANTIVIRAL THERAPY IN NAIVE GENOTYPE 1 HCV INFECTED PATIENTS
10. 363 VIROLOGICAL CHARACTERISTICS OF A LARGE PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC HEPATITIS B NEWLY SEEN IN HEPATOLOGY REFERENCE CENTERS IN FRANCE IN 2008-2010
11. 4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR
12. 615 PROSPECTIVE EVALUATION OF LIVER STIFFNESS DYNAMICS DURING AND AFTER PEGINTERFERON ALPHA-RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C
13. 58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY
14. 793 DYNAMICS OF LIVER STIFFNESS DURING PEGINTERFREON ALPHA-RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C
15. [597] EVOLUTION OF LIVER STIFFNESS MEASUREMENT DURING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C
16. [17] CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C
17. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: Evidence for a role of HCV genotype 3 in steatosis
18. Steatosis is associated with worse histological activity and fibrosis in patients with chronic hepatitis C
19. Histological evaluation of alpha 2a interferon monotherapy in patients with chronic hepatitis C and repeatedly normal aminotransferase levels. A randomized study
20. Should the patients with histologically mild chronic hepatitis C betreated?
21. Alpha 2A interferon monotherapy in patients with chronic hepatitis C and repeatedly normal aminotransferase levels
22. Post-transplant lymphoproliferative disorders (PTLD) after liver transplantation (LT). Role of HCV infection
23. Alcohol intake, even moderate, induces increased histological activity and fibrosis in patients with chronic active hepatitis C
24. Liver iron overload in patients with chronic active hepatitis C. Prevalence, role of the hemochromatosis gene and relation with hepatic histological lesions
25. Mixed cryoglobulinemia after liver transplantation (LT) for HCV cirrhosis. Prevalence and features
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.